Английская Википедия:Efbemalenograstim alfa

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Use American English Шаблон:Use dmy dates Шаблон:Cs1 config Шаблон:Infobox drug Efbemalenograstim alfa, sold under the brand name Ryzneuta, is a medication used to decrease the incidence of infection in chemotherapy-induced neutropenia.[1] It is a leukocyte growth factor.[1] It is given by subcutaneous injection.[1]

Efbemalenograstim alfa is an immunostimulant/colony stimulating factor that belongs to the class of hematopoietic growth factors (granulocyte colony stimulating factor; G CSF) which increase the production and differentiation of mature and functionally active neutrophils from bone marrow precursor cells.[2]

It was approved for medical use in China in May 2023,[3] and in the United States in November 2023.[1][4]

Medical uses

Efbemalenograstim alfa is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adults with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.[5]

Society and culture

Legal status

In January 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Ryzneuta, intended to reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy.[2] The applicant for this medicinal product is Evive Biotechnology Ireland Limited.[2]

References

Шаблон:Reflist

External links

Шаблон:Immunostimulants Шаблон:Portal bar Шаблон:Authority control


Шаблон:Pharma-stub

  1. 1,0 1,1 1,2 1,3 Ошибка цитирования Неверный тег <ref>; для сносок Ryzneuta FDA label не указан текст
  2. 2,0 2,1 2,2 Шаблон:Cite web Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  3. Шаблон:Cite journal
  4. Шаблон:Cite web
  5. Шаблон:Cite web Шаблон:PD-notice